Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Coherent silicon photonic interferometric biosensor with an inexpensive laser source for sensitive label-free immunoassays

  • Leuermann, Jonas|||0000-0001-7321-5190
  • Stamenkovic, Vladimir
  • Ramirez Priego, Patricia|||0000-0001-5657-3279
  • Sánchez-Postigo, Alejandro|||0000-0003-4782-0105
  • Fernandez-Gavela, Adrian|||0000-0002-4562-1308
  • Chapman, Cole A.
  • Bailey, Ryan C.
  • Lechuga, Laura M.|||0000-0001-5187-5358
  • Pérez Inestrosa, Ezequiel|||0000-0001-7546-5273
  • Collado, Daniel
  • Halir, Robert|||0000-0002-5560-3189
  • Molina-Fernandez, Iñigo|||0000-0001-9596-4117
Over the past two decades, integrated photonic sensors have been of major interest to the optical biosensor community due to their capability to detect low concentrations of molecules with label-free operation. Among these, interferometric sensors can be read-out with simple, fixed-wavelength laser sources and offer excellent detection limits but can suffer from sensitivity fading when not tuned to their quadrature point. Recently, coherently detected sensors were demonstrated as an attractive alternative to overcome this limitation. Here we show, for the first time, to the best of our knowledge, that this coherent scheme provides sub-nanogram per milliliter limits of detection in C-reactive protein immunoassays and that quasi-balanced optical arm lengths enable operation with inexpensive Fabry-Perot-type lasers sources at telecom wavelengths.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

  • Alcon, Clara
  • Manzano-Muñoz, Albert|||0000-0003-4039-7391
  • Prada, Estela|||0000-0003-4611-1120
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Soriano, Aroa|||0000-0001-9659-1471
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Gallego, Soledad|||0000-0002-4712-9624
  • Roma, Josep|||0000-0001-7692-6123
  • Samitier, Josep|||0000-0002-1140-3679
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Montero, Joan|||0000-0002-9192-4836
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood and adolescence. Refractory/relapsed RMS patients present a bad prognosis that combined with the lack of specific biomarkers impairs the development of new therapies. Here, we utilize dynamic BH3 profiling (DBP), a functional predictive biomarker that measures net changes in mitochondrial apoptotic signaling, to identify anti-apoptotic adaptations upon treatment. We employ this information to guide the use of BH3 mimetics to specifically inhibit BCL-2 pro-survival proteins, defeat resistance and avoid relapse. Indeed, we found that BH3 mimetics that selectively target anti-apoptotic BCL-xL and MCL-1, synergistically enhance the effect of clinically used chemotherapeutic agents vincristine and doxorubicin in RMS cells. We validated this strategy in vivo using a RMS patient-derived xenograft model and observed a reduction in tumor growth with a tendency to stabilization with the sequential combination of vincristine and the MCL-1 inhibitor S63845. We identified the molecular mechanism by which RMS cells acquire resistance to vincristine: an enhanced binding of BID and BAK to MCL-1 after drug exposure, which is suppressed by subsequently adding S63845. Our findings validate the use of DBP as a functional assay to predict treatment effectiveness in RMS and provide a rationale for combining BH3 mimetics with chemotherapeutic agents to avoid tumor resistance, improve treatment efficiency, and decrease undesired secondary effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining microfluidics with machine learning algorithms for RBC classification in rare hereditary hemolytic anemia

  • Rizzuto, Valeria|||0000-0003-4728-6977
  • Mencattini, Arianna
  • Álvarez-González, Begoña
  • Di Giuseppe, Davide
  • Beneitez Pastor, David|||0000-0002-6541-6600
  • Mañú Pereira, María del Mar|||0000-0003-4770-7460
  • Lopez-Martinez, Maria José
  • Samitier, Josep|||0000-0002-1140-3679
Combining microfluidics technology with machine learning represents an innovative approach to conduct massive quantitative cell behavior study and implement smart decision-making systems in support of clinical diagnostics. The spleen plays a key-role in rare hereditary hemolytic anemia (RHHA), being the organ responsible for the premature removal of defective red blood cells (RBCs). The goal is to adapt the physiological spleen filtering strategy for in vitro study and monitoring of blood diseases through RBCs shape analysis. Then, a microfluidic device mimicking the slits of the spleen red pulp area and video data analysis are combined for the characterization of RBCs in RHHA. This microfluidic unit is designed to evaluate RBC deformability by maintaining them fixed in planar orientation, allowing the visual inspection of RBC's capacity to restre their original shape after crossing microconstrictions. Then, two cooperative learning approaches are used for the analysis: the majority voting scheme, in which the most voted label for all the cell images is the class assigned to the entire video; and the maximum sum of scores to decide the maximally scored class to assign. The proposed platform shows the capability to discriminate healthy controls and patients with an average efficiency of 91%, but also to distinguish between RHHA subtypes, with an efficiency of 82%.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia

  • Manzano-Muñoz, A.
  • Alcon, Clara
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Seyfried, F.
  • Debatin, K.M.
  • Meyer, L.H.
  • Samitier, J.
  • Montero, J.
Multiple targeted therapies are currently explored for pediatric and young adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treatment. However, this new armamentarium of therapies faces an old problem: choosing the right treatment for each patient. The lack of predictive biomarkers is particularly worrying for pediatric patients since it impairs the implementation of new treatments in the clinic. In this study, we used the functional assay dynamic BH3 profiling (DBP) to evaluate two new treatments for BCP-ALL that could improve clinical outcome, especially for relapsed patients. We found that the MEK inhibitor trametinib and the multi-target tyrosine kinase inhibitor sunitinib exquisitely increased apoptotic priming in an NRAS-mutant and in a KMT2A-rearranged cell line presenting a high expression of FLT3, respectively. Following these observations, we sought to study potential adaptations to these treatments. Indeed, we identified with DBP anti-apoptotic changes in the BCL-2 family after treatment, particularly involving MCL-1 - a pro-survival strategy previously observed in adult cancers. To overcome this adaptation, we employed the BH3 mimetic S63845, a specific MCL-1 inhibitor, and evaluated its sequential addition to both kinase inhibitors to overcome resistance. We observed that the metronomic combination of both drugs with S63845 was synergistic and showed an increased efficacy compared to single agents. Similar observations were made in BCP-ALL KMT2A-rearranged PDX cells in response to sunitinib, showing an analogous DBP profile to the SEM cell line. These findings demonstrate that rational sequences of targeted agents with BH3 mimetics, now extensively explored in clinical trials, may improve treatment effectiveness by overcoming anti-apoptotic adaptations in BCP-ALL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preservation of critical quality attributes of mesenchymal stromal cells in 3D bioprinted structures by using natural hydrogel scaffolds

  • Martorell Cedres, Lluis|||0000-0001-9348-4531
  • López-Fernández, Alba|||0000-0001-6072-0294
  • García-Lizarribar, Andrea|||0000-0001-5072-2093
  • Sabata, Roger|||0000-0002-4769-4615
  • Galvez-Martin, Patricia|||0000-0001-9724-8560
  • Samitier, Josep|||0000-0002-1140-3679
  • Vives Armengol, Joaquim|||0000-0001-9719-5235
Three dimensional (3D) bioprinting is an emerging technology that enables complex spatial modeling of cell-based tissue engineering products, whose therapeutic potential in regenerative medicine is enormous. However, its success largely depends on the definition of a bioprintable zone, which is specific for each combination of cell-loaded hydrogels (or bioinks) and scaffolds, matching the mechanical and biological characteristics of the target tissue to be repaired. Therefore proper adjustment of the bioink formulation requires a compromise between: (i) the maintenance of cellular critical quality attributes (CQA) within a defined range of specifications to cell component, and (ii) the mechanical characteristics of the printed tissue to biofabricate. Herein, we investigated the advantages of using natural hydrogel-based bioinks to preserve the most relevant CQA in bone tissue regeneration applications, particularly focusing on cell viability and osteogenic potential of multipotent mesenchymal stromal cells (MSCs) displaying tripotency in vitro, and a phenotypic profile of 99.9% CD105/CD45, 10.3% HLA-DR, 100.0% CD90, and 99.2% CD73/CD31 expression. Remarkably, hyaluronic acid, fibrin, and gelatin allowed for optimal recovery of viable cells, while preserving MSC's proliferation capacity and osteogenic potency in vitro. This was achieved by providing a 3D structure with a compression module below 8.8 ± 0.5 kPa, given that higher values resulted in cell loss by mechanical stress. Beyond the biocompatibility of naturally occurring polymers, our results highlight the enhanced protection on CQA exerted by bioinks of natural origin (preferably HA, gelatin, and fibrin) on MSC, bone marrow during the 3D bioprinting process, reducing shear stress and offering structural support for proliferation and osteogenic differentiation.